bioMérieux: organic growth of 12.8% in Q1
(CercleFinance.com) - bioMérieux Group has reported Q1 2018 sales of 587 million euros for the first three months of 2018, up 3.
4% as reported and up 12.5% like-for-like.
The specialist of in vitro diagnosis explains that this growth is thanks to the performance of molecular biology, with a heavy flu season in the United States, in addition to strong activity in the Asia-Pacific region.
"The recent acquisition of Astute Medical fits perfectly with our strategy to offer high medical value tests to improve patients' care", added CEO Alexandre Mérieux.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
4% as reported and up 12.5% like-for-like.
The specialist of in vitro diagnosis explains that this growth is thanks to the performance of molecular biology, with a heavy flu season in the United States, in addition to strong activity in the Asia-Pacific region.
"The recent acquisition of Astute Medical fits perfectly with our strategy to offer high medical value tests to improve patients' care", added CEO Alexandre Mérieux.
Copyright (c) 2018 CercleFinance.com. All rights reserved.